ADHD Pharmacotherapy and Mortality in Individuals With ADHD
Beyond day-to-day symptom control, what does staying on treatment change about the bigger risks — accidents, substance use, driving — in my situation?
Well-supported by good-quality research. how we score evidence
Caveat on this rating: Observational despite target-trial-emulation design; one senior author reports grants and personal fees from Shire/Takeda outside the work; results cover ADHD medications as a class, mostly stimulants.
Among 148,578 Swedish people newly diagnosed with ADHD, starting medication was associated with 21% lower all-cause mortality over 2 years — about 9 fewer deaths per 10,000 people — driven mainly by fewer deaths from unnatural causes such as accidents and overdoses.
Worth asking
Beyond day-to-day symptom control, what does staying on treatment change about the bigger risks — accidents, substance use, driving — in my situation?
What it is FDA approved for
Read off the label. Trial duration and approval year are shown only where they were recorded — never inferred.
- Attention-deficit/hyperactivity disorder (ADHD)
- Narcolepsy
Source
ADHD Pharmacotherapy and Mortality in Individuals With ADHD — Li L, et al. (2024)
Top-tier peer-reviewed journal
Read the source: https://doi.org/10.1001/jama.2024.0851
DOI: 10.1001/jama.2024.0851
How this was scored
- Study design
- Cohort study
- Funding
- Independently funded
- Published in
- Top-tier peer-reviewed journal
- Sample size
- 148,578
- Preregistered
- No
- Conflicts disclosed
- Yes
- Independent of proponent
- Yes
- Retracted
- No
Read the full scoring rubric, including what it can't tell you.
Published August 19, 2026.
Questions
How strong is the evidence behind this?
Resolv rates this source "strong evidence". Well-supported by good-quality research. It scores 79 out of 100 on our published rubric. One caveat travels with that badge: Observational despite target-trial-emulation design; one senior author reports grants and personal fees from Shire/Takeda outside the work; results cover ADHD medications as a class, mostly stimulants. The score is calculated from recorded facts about the source — study design, funding, publication venue, sample size, preregistration — not typed in by an editor.
What is the source for this?
ADHD Pharmacotherapy and Mortality in Individuals With ADHD — Li L, et al. (2024). Published in: Top-tier peer-reviewed journal. DOI: 10.1001/jama.2024.0851. The full source is linked on this page so you can read it yourself.
Who paid for this research, and does that matter?
Study design: Cohort study. Funding: Independently funded. The researchers were independent of whoever benefits from the result. Industry sponsorship is one of the most reliably measured biases in medicine, which is why funding carries real weight in the score rather than sitting in a footnote.
Is amphetamine (Adderall, Mydayis, Evekeo), adderall, mydayis, evekeo FDA approved?
Yes — FDA approved for Attention-deficit/hyperactivity disorder (ADHD), Narcolepsy. Approval is for a specific indication, not for everything the drug is prescribed for.
Is this medical advice?
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.